FLINT, Mich. – April 5, 2016 – The nation’s largest independent specialty pharmacy has been selected to Lilly’s distribution network for adults with moderate to severe plaque psoriasis drug TALTZ® (ixekizumab).

Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today that it has been selected to the Eli Lilly and Company limited-distribution panel to distribute TALTZ® (ixekizumab). TALTZ® was recently approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe plaque psoriasis.

To learn more about Diplomat’s psoriasis program, click here.

Psoriasis is an autoimmune condition that affects the skin, causing patches of redness and irritation. The condition occurs more often in patients with a family history of the disease, with symptoms typically starting between the ages of 15 and 35. The most common form is plaque psoriasis; patients with this form develop raised, red patches of skin covered with a silvery-white layer of dead skin cells.

“Psoriasis is a serious chronic disease that can have debilitating symptoms,” said Gary Kadlec, Diplomat president. “TALTZ® enables patients an important treatment option.”

TALTZ® is indicated for the treatment of of moderate-to-severe plaque psoriasis in adult patients who are candidates for systematic therapy or phototherapy. TALTZ® is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.

TALTZ® is manufactured by Eli Lilly and Company. Please see full prescribing information for TALTZ® here.

 

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2015 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.

###

CONTACT:
Kali Lucas, Public Relations Coordinator
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP,
Senior Vice President, Clinical Services,
Education and Human Resources
810.768.9863 | grice@diplomat.is

Twitter